Recent Exact Sciences Corporation financials show accelerating revenue growth and stable margins, despite ongoing investments in screening and MRD. While EXAS maintains leadership in stool-based CRC ...

If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...

Abbott is getting into cancer testing with its $21 billion acquisition Exact Sciences, the maker of the game-changing colorectal cancer test Cologuard. Abbott markets well-known diagnostics for ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Abbott Laboratories ABT-0.83%decrease; red down pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS-0.16%decrease; red down pointing triangle in a deal valued at about ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business. This marks one of Abbott's largest deals ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories agreed to acquire cancer-screening ...

Investing.com -- Exact Sciences (NASDAQ:EXAS) stock soared 17% Thursday, building on Wednesday’s 24% surge after Abbott (NYSE:ABT) announced plans to acquire the cancer diagnostics company in a deal ...

North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...